Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149


Single-Cycle Atomic Layer Deposition on Bulk Wood Lumber for Managing Moisture Content, Mold Growth, and Thermal Conductivity.

Gregory SA, McGettigan CP, McGuinness EK, Rodin DM, Yee SK, Losego MD.

Langmuir. 2020 Feb 25;36(7):1633-1641. doi: 10.1021/acs.langmuir.9b03273. Epub 2020 Feb 13.


Thermoelectrics that bend but don't break.

Gregory SA, Losego MD.

Nat Mater. 2019 Jan;18(1):3-4. doi: 10.1038/s41563-018-0227-x. No abstract available.


Aqueous Zinc Compounds as Residual Antimicrobial Agents for Textiles.

Holt BA, Gregory SA, Sulchek T, Yee S, Losego MD.

ACS Appl Mater Interfaces. 2018 Mar 7;10(9):7709-7716. doi: 10.1021/acsami.7b15871. Epub 2018 Feb 26.


Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.

Karmali R, Larson ML, Shammo JM, Gregory SA, O'Brien T, Venugopal P.

Mol Clin Oncol. 2017 Apr;6(4):627-633. doi: 10.3892/mco.2017.1169. Epub 2017 Feb 17.


Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S.

Blood Cancer J. 2016 Mar 11;6:e404. doi: 10.1038/bcj.2016.9.


CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.

Leonard JP, Gregory SA, Smith H, Horner TJ, Williams VC, Giampietro P, Lin TS.

Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):191-6. doi: 10.1016/j.clml.2015.12.011. Epub 2016 Jan 4.


Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP.

Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15. Review.


Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma".

Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI.

Ann Oncol. 2014 Jul;25(7):1449. doi: 10.1093/annonc/mdu179. Epub 2019 Dec 4. No abstract available.


Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW Jr.

J Clin Oncol. 2014 Jun 10;32(17):1797-803. doi: 10.1200/JCO.2012.43.9273. Epub 2014 May 5.


Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.

Dakhil S, Hermann R, Schreeder MT, Gregory SA, Monte M, Windsor KS, Hurst D, Chai A, Brewster M, Richards P.

Leuk Lymphoma. 2014 Oct;55(10):2335-40. doi: 10.3109/10428194.2013.877135. Epub 2014 Mar 7.


Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results.

Ruan J, Gregory SA, Christos P, Martin P, Furman RR, Coleman M, Leonard JP.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):107-13. doi: 10.1016/j.clml.2013.10.002. Epub 2013 Nov 18.


The Prognostic Significance of Resting Regional Left Ventricular Function in Patients With Varying Degrees of Myocardial Ischemia.

Kilcullen NM, Uthamalingam S, Gurm GS, Gregory SA, Picard MH.

Cardiol Res. 2013 Dec;4(6):178-185. doi: 10.4021/cr240w. Epub 2014 Jan 2.


A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI.

Ann Oncol. 2013 Dec;24(12):3076-81. doi: 10.1093/annonc/mdt414. Epub 2013 Oct 20. Erratum in: Ann Oncol. 2014 Jul;25(7):1449. Ann Oncol. 2014 Jul;25(7):1449.


Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI.

J Clin Oncol. 2013 Nov 20;31(33):4199-206. doi: 10.1200/JCO.2012.48.3685. Epub 2013 Oct 14.


Ocular adnexal MALTomas: case series of patients treated with primary radiation.

Russell W, Herskovic A, Gessert D, Cohen JA, Rubenstein JB, Gregory SA.

Clin Adv Hematol Oncol. 2013 Apr;11(4):209-14.


Successful treatment of hepatosplenic T-cell lymphoma with ESHAP followed by autologous stem cell transplant.

Chalmers AW, Katz DA, Miller IJ, Gregory SA.

Clin Adv Hematol Oncol. 2013 Feb;11(2):109-13. No abstract available.


Magnetic control of a meta-molecule.

Stenning GB, Bowden GJ, Maple LC, Gregory SA, Sposito A, Eason RW, Zheludev NI, de Groot PA.

Opt Express. 2013 Jan 28;21(2):1456-64. doi: 10.1364/OE.21.001456.


Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients.

Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd.

J Leukoc Biol. 2013 Jan;93(1):161-70. doi: 10.1189/jlb.0612301. Epub 2012 Nov 7.


Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.

Weiner RB, Baggish AL, Chen-Tournoux A, Marshall JE, Gaggin HK, Bhardwaj A, Mohammed AA, Rehman SU, Barajas L, Barajas J, Gregory SA, Moore SA, Semigran MJ, Januzzi JL Jr.

Eur J Heart Fail. 2013 Mar;15(3):342-51. doi: 10.1093/eurjhf/hfs180. Epub 2012 Nov 6.


Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.

Gaggin HK, Mohammed AA, Bhardwaj A, Rehman SU, Gregory SA, Weiner RB, Baggish AL, Moore SA, Semigran MJ, Januzzi JL Jr.

J Card Fail. 2012 Aug;18(8):626-34. doi: 10.1016/j.cardfail.2012.05.005. Epub 2012 Jun 19.


CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.

Christopherson KW 2nd, Frank RR, Jagan S, Paganessi LA, Gregory SA, Fung HC.

Exp Hematol. 2012 Nov;40(11):945-52. doi: 10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27.


Clinical and laboratory features of myelofibrosis and limitations of current therapies.

Gregory SA, Mesa RA, Hoffman R, Shammo JM.

Clin Adv Hematol Oncol. 2011 Sep;9(9 Suppl 22):1-16.


Multiple myeloma with multiple extramedullary plasmacytomas.

Nangia JR, Lakhani AA, Loew JM, Gregory SA.

Clin Adv Hematol Oncol. 2011 Aug;9(8):630-2. No abstract available.


Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.

Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ.

J Am Coll Cardiol. 2011 Oct 25;58(18):1881-9. doi: 10.1016/j.jacc.2011.03.072.


Male breast uptake of 99m-Tc sestamibi in myocardial perfusion imaging.

Uthamalingam S, Sidhu MS, Gurm GS, Yasuda T, Francis S, Scott J, Gregory SA.

Int J Cardiol. 2012 Mar 8;155(2):e22-3. doi: 10.1016/j.ijcard.2011.06.080. Epub 2011 Jul 13. No abstract available.


Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.

Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P.

Leuk Lymphoma. 2011 Nov;52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24.


Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22.


Navy Prototype Optical Interferometer observations of geosynchronous satellites.

Hindsley RB, Armstrong JT, Schmitt HR, Andrews JR, Restaino SR, Wilcox CC, Vrba FJ, Benson JA, DiVittorio ME, Hutter DJ, Shankland PD, Gregory SA.

Appl Opt. 2011 Jun 10;50(17):2692-8. doi: 10.1364/AO.50.002692.


Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.

Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, McLaughlin P, Press O, Zelenetz AD.

Leuk Lymphoma. 2011 Jul;52(7):1188-99. doi: 10.3109/10428194.2011.570396. Epub 2011 May 23. Review.


Bendamustine's emerging role in the management of lymphoid malignancies.

Rummel MJ, Gregory SA.

Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004. Review.


In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice.

Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA, Boggio LN, Fung HC, Gregory SA, Christopherson KW 2nd.

Exp Hematol. 2011 May;39(5):580-590.e1. doi: 10.1016/j.exphem.2011.01.012. Epub 2011 Feb 1.


Intravascular B-cell lymphoma following nodal diffuse large B-cell lymphoma.

Katz DA, Miller IJ, Gregory SA.

Clin Adv Hematol Oncol. 2010 Sep;8(9):637-41. No abstract available.


High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma.

Tuncer HH, Gregory SA, Fung HC.

Bone Marrow Transplant. 2011 Aug;46(8):1156-7. doi: 10.1038/bmt.2010.251. Epub 2010 Oct 25. No abstract available.


The future of CD20 monoclonal antibody therapy in B-cell malignancies.

Czuczman MS, Gregory SA.

Leuk Lymphoma. 2010 Jun;51(6):983-94. doi: 10.3109/10428191003717746. Review.


Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.

Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.


New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.

Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA.

Oncologist. 2009;14 Suppl 2:52-4. doi: 10.1634/theoncologist.2009-S2-52. Review. No abstract available.


Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.

Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M.

Oncologist. 2009;14 Suppl 2:4-16. doi: 10.1634/theoncologist.2009-S2-4.


New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Introduction.

Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA.

Oncologist. 2009;14 Suppl 2:1-3. doi: 10.1634/theoncologist.2009-S2-1. No abstract available.


Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL.

J Clin Oncol. 2009 Oct 20;27(30):5023-30. doi: 10.1200/JCO.2008.17.7980. Epub 2009 Sep 21.


Delayed heart rate recovery after adenosine stress testing with supplemental arm exercise predicts mortality.

Akutsu Y, Gregory SA, Kardan A, Zervos GD, Thomas GS, Gewirtz H, Yasuda T.

J Nucl Cardiol. 2009 Jan-Feb;16(1):54-62. doi: 10.1007/s12350-008-9014-4. Epub 2009 Jan 20.


Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E.

Blood. 2009 Apr 16;113(16):3673-8. doi: 10.1182/blood-2008-09-177329. Epub 2008 Nov 17.


Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture.

Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd.

Transfusion. 2008 Dec;48(12):2638-44. doi: 10.1111/j.1537-2995.2008.01926.x. Epub 2008 Sep 16.


An extended dosing regimen of epoetin alfa 60,000 units every 2 weeks in anemic patients with cancer receiving chemotherapy.

Gregory SA, Xie J, Szczudlo T, Williams D, Woodman RC, Wilhelm FE.

Support Cancer Ther. 2007 Sep 1;4(4):225-32. doi: 10.3816/SCT.2007.n.019.


Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin's Lymphoma.

Gregory SA.

Support Cancer Ther. 2006 Jul 1;3(4):232-9. doi: 10.3816/SCT.2006.n.021.


Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.

Leonard JP, Gregory SA, Maloney DG, Vose JM, Younes A, Zelenetz AD.

Clin Adv Hematol Oncol. 2008 Jun;6(6):437-45. Review.


Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea.

Green SM, Martinez-Rumayor A, Gregory SA, Baggish AL, O'Donoghue ML, Green JA, Lewandrowski KB, Januzzi JL Jr.

Arch Intern Med. 2008 Apr 14;168(7):741-8. doi: 10.1001/archinte.168.7.741.


NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.

Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA.

Leukemia. 2008 May;22(5):998-1006. doi: 10.1038/leu.2008.15. Epub 2008 Feb 21.


Evaluation and management of respiratory muscle dysfunction in ALS.

Gregory SA.

NeuroRehabilitation. 2007;22(6):435-43. Review.


Emerging treatments for indolent lymphoma.

Cheson BD, Gregory SA, Marcus R.

Clin Adv Hematol Oncol. 2007 May;5(5 Suppl 8):1-9; quiz 11-2.


Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.

Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ.

Clin Cancer Res. 2007 Oct 15;13(20):6168-74.

Supplemental Content

Loading ...
Support Center